Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
B-Cell Lymphoma
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
May 1st, 2007
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, reported that data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that fusion proteins combining the anti-cancer cytokines alpha interferon and interleukin 2 (IL-2) with 2aG4, a bavituximab equivalent, demonstrated potent anti-cancer activity in preclinical models of B-cell lymphoma and melanoma. In these studies, the antibody-cytokine fusion proteins generated a robust anti-tumor response without any observable toxicity. These immunocytokine...
Source: Cancer Weekly (2007-05-01)
|
